DRREDDY.NS Profit & Loss
Dr. Reddy's Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 9 years on file
(FY2017-18 to FY2025-26)
· fetched 2026-08-23 21:45
| Line item | FY2017-18 | FY2018-19 | FY2019-20 | FY2020-21 | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹142.81 Bn | ₹154.48 Bn | ₹175.17 Bn | ₹190.47 Bn | ₹215.45 Bn | ₹246.70 Bn | ₹280.11 Bn | ₹326.44 Bn | ₹337.00 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | ₹142.81 Bn | ₹154.48 Bn | ₹175.17 Bn | ₹190.47 Bn | ₹215.45 Bn | ₹246.70 Bn | ₹280.11 Bn | ₹326.44 Bn | ₹337.00 Bn | SegmentRevenueFromOperations |
| Other Income | ₹1.55 Bn | ₹3.38 Bn | ₹6.21 Bn | ₹2.91 Bn | ₹4.84 Bn | ₹10.55 Bn | ₹8.94 Bn | ₹10.97 Bn | ₹13.58 Bn | OtherIncome |
| Total Income | ₹144.36 Bn | ₹157.86 Bn | ₹181.38 Bn | ₹193.39 Bn | ₹220.30 Bn | ₹257.25 Bn | ₹289.05 Bn | ₹337.41 Bn | ₹350.59 Bn | Income |
| Cost of Materials Consumed | ₹26.31 Bn | ₹28.89 Bn | ₹29.85 Bn | ₹42.96 Bn | ₹43.12 Bn | ₹42.20 Bn | ₹44.90 Bn | ₹56.84 Bn | ₹65.01 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹14.50 Bn | ₹18.81 Bn | ₹25.46 Bn | ₹25.74 Bn | ₹34.84 Bn | ₹33.67 Bn | ₹43.99 Bn | ₹48.41 Bn | ₹61.62 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-0.41 Bn | ₹-2.75 Bn | ₹0.24 Bn | ₹-7.91 Bn | ₹-3.54 Bn | ₹0.71 Bn | ₹-6.80 Bn | ₹-5.45 Bn | ₹-4.24 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹32.15 Bn | ₹33.56 Bn | ₹33.80 Bn | ₹36.30 Bn | ₹38.86 Bn | ₹46.47 Bn | ₹50.30 Bn | ₹55.80 Bn | ₹59.91 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹0.79 Bn | ₹0.89 Bn | ₹0.98 Bn | ₹0.97 Bn | ₹0.96 Bn | ₹1.43 Bn | ₹1.71 Bn | ₹2.83 Bn | ₹3.74 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹10.77 Bn | ₹11.35 Bn | ₹11.63 Bn | ₹12.29 Bn | ₹11.65 Bn | ₹12.50 Bn | ₹14.70 Bn | ₹17.04 Bn | ₹20.59 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹46.75 Bn | ₹44.19 Bn | ₹61.12 Bn | ₹54.69 Bn | ₹64.50 Bn | ₹60.16 Bn | ₹68.39 Bn | ₹85.37 Bn | ₹90.17 Bn | OtherExpenses |
| Total Expenses | ₹130.86 Bn | ₹134.94 Bn | ₹163.08 Bn | ₹165.03 Bn | ₹190.38 Bn | ₹197.14 Bn | ₹217.19 Bn | ₹260.83 Bn | ₹296.79 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹13.50 Bn | ₹22.92 Bn | ₹18.30 Bn | ₹28.36 Bn | ₹29.91 Bn | ₹60.12 Bn | ₹71.86 Bn | ₹76.58 Bn | ₹53.79 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹13.50 Bn | ₹22.92 Bn | ₹18.30 Bn | ₹28.36 Bn | ₹29.91 Bn | ₹60.12 Bn | ₹71.86 Bn | ₹76.58 Bn | ₹53.79 Bn | ProfitBeforeTax |
| Tax Expense | ₹4.38 Bn | ₹3.86 Bn | ₹-1.40 Bn | ₹9.32 Bn | ₹8.79 Bn | ₹15.41 Bn | ₹16.23 Bn | ₹19.54 Bn | ₹12.35 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹9.47 Bn | ₹19.50 Bn | ₹20.26 Bn | ₹19.52 Bn | ₹21.82 Bn | ₹45.07 Bn | ₹55.78 Bn | ₹57.25 Bn | ₹41.58 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹9.47 Bn | ₹19.50 Bn | ₹20.26 Bn | N/A | N/A | N/A | ₹0.00 Bn | ₹56.55 Bn | ₹41.96 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹57.08 | ₹117.53 | ₹122.22 | ₹117.67 | ₹131.57 | ₹271.47 | ₹335.22 | ₹67.89 | ₹50.41 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹56.96 | ₹117.33 | ₹121.99 | ₹117.34 | ₹131.21 | ₹270.90 | ₹334.59 | ₹67.79 | ₹50.35 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from DRREDDY.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).